trial

A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia

NCTId NCT02164981
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 60 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2017-03-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2015-05-01
Primary completion
2017-03-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Sodium nitroprusside

Sponsors

Massachusetts General HospitalLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

2
Maurizio Fava, MDPrincipal Investigator
Roy Perlis, MD MScPrincipal Investigator

Sites

4 total
Boston, United StatesWorcester, United StatesGlen Oaks, United StatesNew York, United States

Linked catalysts

1
A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symp — primary completion2017-03-31

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE2
Primary Completion Date
2017-03-31
Status
COMPLETED
relationships
The graph out of here
drug
Sodium nitroprusside
drug
lead_sponsor
Massachusetts General Hospital
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Maurizio Fava, MD
person
Roy Perlis, MD MSc
person